Dimerix Limited announces top-line results from a recent pharmacokinetic (PK) study of an extended release tablet formulation for their DMX-200 program targeting Chronic Kidney Disease (CKD).
The study found a newly formulated extended release tablet of DMX-200 taken twice daily (against three times daily for the previous formulation) increases the duration of release of DMX-200 in the human body. The extended release formulation provides a clear benefit by extendingthe half-life of propagermanium in patients, and will allow a reduced number of daily doses in further studies.
The full ASX announcement is available here.
Dimerix Ltd. published this content on 08 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 08 January 2018 00:44:08 UTC.
Original documenthttp://dimerix.com/dmx-200-dosage-optimisation-study-successfully-completed-preparation-phase-2b-trial/
Public permalinkhttp://www.publicnow.com/view/D1FFBAAEA15C581B6580FC34B3EE328FA6C57B54
